Moriguchi Shigeki, Marszalec William, Zhao Xilong, Yeh Jay Z, Narahashi Toshio
Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, IL 60611-3008, USA.
J Pharmacol Exp Ther. 2003 Oct;307(1):160-7. doi: 10.1124/jpet.103.050823. Epub 2003 Jun 12.
Nefiracetam is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and post-stroke vascular-type dementia. In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems has been found and is thought to play an important role in impairment of cognition, learning and memory. We have previously shown that the activity of neuronal nicotinic acetylcholine receptors is potently augmented by nefiracetam. The present study was undertaken to elucidate the mechanism of action of nefiracetam on glutamatergic receptors. Currents were recorded from rat cortical neurons in long-term primary culture using the whole-cell patch-clamp technique at a holding potential of -70 mV in Mg2+-free solutions. N-Methyl-D-aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam resulting in a bell-shaped dose-response curve. The minimum effective nefiracetam concentration was 1 nM, and the maximum potentiation to 170% of the control was produced at 10 nM. Nefiracetam potentiation occurred at high NMDA concentrations that evoked the saturated response, and in a manner independent of NMDA concentrations ranging from 3 to 1,000 microM. Glycine at 3 microM potentiated NMDA currents but this effect was attenuated with an increasing concentration of nefiracetam from 1 to 10,000 nM. 7-Chlorokynurenic acid at 1 microM prevented nefiracetam from potentiating NMDA currents. Nefiracetam at 10 nM shifted the dose-response relationship for the 7-chlorokynurenic acid inhibition of NMDA currents in the direction of higher concentrations. Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid- and kainate-induced currents were not significantly affected by application of 10 nM nefiracetam. It was concluded that nefiracetam potentiated NMDA currents through interactions with the glycine binding site of the NMDA receptor.
奈非西坦是一种正在研发的新型吡咯烷酮类益智药物,用于治疗阿尔茨海默病型和中风后血管型痴呆。在阿尔茨海默病患者的大脑中,已发现胆碱能和谷氨酸能系统均下调,并被认为在认知、学习和记忆障碍中起重要作用。我们之前已表明,奈非西坦可有效增强神经元烟碱型乙酰胆碱受体的活性。本研究旨在阐明奈非西坦对谷氨酸能受体的作用机制。在无镁溶液中,使用全细胞膜片钳技术,在 -70 mV 的钳制电位下,记录长期原代培养的大鼠皮质神经元中的电流。通过浴加奈非西坦,N-甲基-D-天冬氨酸(NMDA)诱发的电流得到极大且可逆的增强,产生钟形剂量反应曲线。奈非西坦的最小有效浓度为 1 nM,在 10 nM 时产生最大增强,达到对照的 170%。奈非西坦的增强作用发生在诱发饱和反应的高 NMDA 浓度下,且与 3 至 1000 μM 的 NMDA 浓度无关。3 μM 的甘氨酸可增强 NMDA 电流,但随着奈非西坦浓度从 1 增加到 10000 nM,这种作用减弱。1 μM 的 7-氯犬尿氨酸可阻止奈非西坦增强 NMDA 电流。10 nM 的奈非西坦使 7-氯犬尿氨酸抑制 NMDA 电流的剂量反应关系向更高浓度方向移动。应用 10 nM 奈非西坦对α-氨基-3-羟基-5-甲基异恶唑-4-丙酸和海人藻酸诱发的电流无显著影响。得出的结论是,奈非西坦通过与 NMDA 受体的甘氨酸结合位点相互作用增强 NMDA 电流。